Tg TherapeuticsTGTX.OValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, Tg Therapeutics (TGTX.O) trades at a P/E of 18.70x, P/B of 13.70x, P/S of 10.30x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 38th percentile over the trailing 10Y window (vs. 38th percentile over 3Y); P/B sits at the 50th percentile over the trailing 10Y window (vs. 31st percentile over 3Y); P/S sits at the 15th percentile over the trailing 10Y window (vs. 51st percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 36th percentile within its industry and the 49th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.10%, ranking at the 96th percentile over the trailing 20Y window.
The P/E and P/B long-window percentiles differ by only 11.8 points, pointing to a consistent valuation read across both metrics. Relative to industry peers, its P/E shows a deeper discount than it does against the broader market. Shareholder returns here lean heavily on buybacks rather than cash dividends. Tg Therapeutics operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NASDAQ: TGTX · TGTX
Want the full picture on whether Tg Therapeutics (TGTX.O) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 18.70 | ||||||
| P/B (MRQ) | 13.70 | ||||||
| P/S (TTM) | 10.30 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 1.10% |